Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin for methamphetamine dependence during Matrix maintenance treatment
IRCT20171129037673N1Phase 2Completed
- Sponsor
- Kashan University of Medical Sciences
- Start
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in methamphetamine use disorder (MUD) comparing Oxytocin with Placebo (2 arms). Primary endpoints: Methamphetamine craving, Depression and 3 more. Started Dec 2017; status: completed.
02
Drugs
oxytocin
03
Conditions
methamphetamine use disorder (MUD)
Beyond the preview
Go deeper on IRCT20171129037673N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20171129037673N1.